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Introduction
B cells play a central role in the pathogenesis of many
autoimmune diseases. Therefore, understanding the
mechanisms that regulate B-cell tolerance in humans is
important for the development of new therapeutic stra-
tegies. Patients with monogenic diseases provide rare
opportunities to study the impact of specific gene muta-
tions on the regulation of human B cell tolerance. By
this, we could show that alterations in B-cell receptor
(BCR) and Toll-like receptor (TLR) signaling pathways
result in defective central B-cell tolerance.
Objectives
The aim was to further dissect the BCR and TLR signaling
pathways involved in the establishement of central B-cell
tolerance in humans. In detail, we aimed to analyze the
role of CD19 in mediating central B-cell tolerance in
humans. CD19 is a co-receptor expressed on B cells and is
involved in the amplification of B-cell responses; its
expression is decreased in patients with systemic lupus
erythematosus (SLE), suggesting that proper CD19 expres-
sion may normally prevent autoimmunity. Additionally,
CD19-deficient patients suffering from an antibody defi-
ciency are also prone to develop systemic autoimmune
diseases resembling SLE.
Methods
To test the function of the central B-cell tolerance
checkpoint in humans, we analyzed by ELISA and
immunofluorescence tests the reactivity of recombinant
antibodies cloned from single transitional B cells from
individuals carrying CD19 mutations. Additionally, we
analyzed alterations in TLR and BCR signaling pathways
in CD19-deficient human B cells using flow cytometry
and immunoblotting.
Results
We found that individuals carrying CD19 mutations dis-
played defective central B-cell tolerance checkpoints. In
addition, CD19-deficient transitional B cells were
enriched in anti-nuclear clones, a feature previously
observed in IRAK4- and MYD88-deficient patients in
which TLR7/9 sensing nucleic acids cannot signal.
Therefore, we investigated the functions of these TLRs
in B cells in the absence of CD19 expression. CD19-
deficient human B cells displayed defective up-regula-
tion of activation markers after TLR7/9 triggering and
failed to induce BTK, AKT but not p38 MAPK or I-Ba
phosphorylation after TLR7/9 stimulation. Additionally,
inhibitors blocking BTK, AKT and PI3K function as
well as mutations in BTK impaired CD19-dependent
TLR7/9 responses in healthy donor’s B cells.
Conclusion
Thus, CD19 and its PI3K/BTK/AKT signaling pathway is
essential for B-cell activation and the establishment of cen-
tral human B-cell tolerance by mediating the function of
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